IDH2 and central nervous system cancer: In addition to peculiar clinical characteristics such as younger age at diagnosis and an overall better prognosis, accumulating evidence allowed identifying IDH-mutated gliomas as a completely different entity at the molecular level compared to the IDH-wt counterparts [14].